Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3741528,bioavailability,"In comparison to the reference capsule formulation, the tablet had statistically significantly lower (75%) bioavailability.",Suprofen sustained release kinetics in healthy male volunteers. 1st communication: a single dose open crossover bioavailability study of suprofen sustained release tablets versus capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741528/),%,75,116795,DB00870,Suprofen
,6685517,peak plasma time,"In a bioavailability study (study A) suprofen, given as intramuscular injection was absorbed more rapidly (mean peak plasma time 20.0 min) than from the capsule formulation (mean peak plasma time 57.5 min).",Suprofen kinetics in healthy male volunteers after intramuscular injection of increasing dosages. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6685517/),min,20.0,149268,DB00870,Suprofen
,6685517,peak plasma time,"In a bioavailability study (study A) suprofen, given as intramuscular injection was absorbed more rapidly (mean peak plasma time 20.0 min) than from the capsule formulation (mean peak plasma time 57.5 min).",Suprofen kinetics in healthy male volunteers after intramuscular injection of increasing dosages. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6685517/),min,57.5,149269,DB00870,Suprofen
,6685517,first order absorption rate,"Individual plasma concentration profiles (study B) were described by a 2-compartmental model with a mean first order absorption rate of 0.095 min-1, a rapid mean disposition rate alpha of 0.025 min-1 and an apparent terminal plasma elimination rate beta of 0.004 min-1.",Suprofen kinetics in healthy male volunteers after intramuscular injection of increasing dosages. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6685517/),1/[min],0.095,149270,DB00870,Suprofen
,6685517,disposition rate alpha,"Individual plasma concentration profiles (study B) were described by a 2-compartmental model with a mean first order absorption rate of 0.095 min-1, a rapid mean disposition rate alpha of 0.025 min-1 and an apparent terminal plasma elimination rate beta of 0.004 min-1.",Suprofen kinetics in healthy male volunteers after intramuscular injection of increasing dosages. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6685517/),1/[min],0.025,149271,DB00870,Suprofen
,6685517,apparent terminal plasma elimination rate beta,"Individual plasma concentration profiles (study B) were described by a 2-compartmental model with a mean first order absorption rate of 0.095 min-1, a rapid mean disposition rate alpha of 0.025 min-1 and an apparent terminal plasma elimination rate beta of 0.004 min-1.",Suprofen kinetics in healthy male volunteers after intramuscular injection of increasing dosages. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6685517/),1/[min],0.004,149272,DB00870,Suprofen
,4026925,absolute bioavailability,The absolute bioavailability of suprofen taken as one capsule was 92.2% based on AUC-values and did not indicate a first-pass effect.,Pharmacokinetics and bioavailability of suprofen injection solution after intravenous application versus capsules on six healthy male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026925/),%,92.2,207891,DB00870,Suprofen
,4026925,half-life,Assuming first order input a half-life of 23 min could be derived based on point-area deconvolution.,Pharmacokinetics and bioavailability of suprofen injection solution after intravenous application versus capsules on six healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026925/),min,23,207892,DB00870,Suprofen
